Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$460.73 ▲ +8.90
(+1.97%)
MKT CAP: $249.09B • VOL: 2.98M
52W L $292 52W H $476
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$387
MEDIAN
$516
MEAN
$525
HIGH
$627
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AMGN TAPE
AMGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $557.48 | $529.84 | 2025-02-14 | $419.26 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $580.52 | $543.66 | 2025-02-06 | $433.09 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $525.23 | $506.80 | 2025-01-29 | $442.30 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $469.94 | — | 2025-01-17 | $451.52 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $405.44 | $437.69 | 2025-01-09 | $410.05 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $548.27 | $479.16 | 2024-12-18 | $400.84 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $446.91 | $465.34 | 2024-12-04 | $428.48 | -4.3% | 48% | C |